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Abstract
Background: Several chemical UV filters/absorbers ('UV filters' hereafter) have 
endocrine-disrupting properties in vitro and in vivo. Exposure to these chemicals, 
especially during prenatal development, is of concern.
Objectives: To examine maternal exposure to UV filters, associations with maternal 
thyroid hormone, with growth factor concentrations as well as to birth outcomes.
Methods: Prospective study of 183 pregnant women with 2nd trimester serum and urine 
samples available. Maternal concentrations of the chemical UV filters benzophenone-1 
(BP-1) and benzophenone-3 (BP-3) in urine and 4-hydroxy-benzophenone (4-HBP) in 
serum were measured by liquid chromatography–tandem mass spectrometry  
(LC–MS/MS). The relationships between 2nd trimester maternal concentrations of the 
three chemical UV filters and maternal serum concentrations of thyroid hormones and 
growth factors, as well as birth outcomes (weight, height, and head and abdominal 
circumferences) were examined.
Results: Positive associations between maternal serum concentrations of 4-HBP and 
triiodothyronine (T3), thyroxine (T4), insulin-like growth factor I (IGF-I) and its binding 
protein IGFBP3 were observed in mothers carrying male fetuses. Male infants of mothers 
in the middle 4-HBP exposure group had statistically significantly lower weight and 
shorter head and abdominal circumferences at birth compared to the low exposure group.
Conclusions: Widespread exposure of pregnant women to chemical UV filters and the 
possible impact on maternal thyroid hormones and growth factors, and on fetal growth, 
calls for further studies on possible long-term consequences of the exposure to UV filters 
on fetal development and children’s health.
Introduction
Several recent studies have shown that human exposure to 
chemicals used as UV filters/absorbers is prevalent (1, 2, 3, 
4, 5). Exposure to UV filters occurs not only by intentional 
use of sunscreens. Due to their ability to absorb UV light, 
UV filters are used as ‘UV-absorbers’ in a wide range of 
everyday products such as for protecting colors from 
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bleaching, plastic from becoming friable in the sunlight 
or as photo-initiators in ink (6, 7, 8, 9, 10, 11, 12). For 
practical reasons, we will refer to all of these chemicals as 
‘UV filters’ throughout this paper, regardless of their use in 
industry. The widespread use of chemical UV filters results 
in human exposure throughout the year (2). The prevalent 
human exposure to UV filters is of concern as several of 
these chemicals have endocrine-disrupting properties 
demonstrated in in vitro animal and human studies (13, 
14, 15, 16, 17, 18, 19, 20, 21). We recently investigated 
the concentrations of seven different chemical UV filters 
in maternal blood and urine, and in amniotic fluid, 
and found that the UV filters benzophenone-1 (BP-1), 
benzophenone-3 (BP-3) and 4-hydroxybenzophenone 
(4-HBP) were present in the majority of pregnant women 
(3). Although concentrations were significantly lower in 
amniotic fluid samples, BP-1 and BP-3 as well as 4-HBP 
could also be found in the cord blood of several of the 
participants, indicating that these compounds might also 
cross the placenta and reach the fetus.
Successful intrauterine development of the human 
fetus is highly dependent on hormonal regulation, 
and disturbance of hormones during pregnancy might 
therefore have dramatic consequences for the development 
of the unborn child. In humans, urinary concentrations 
of BP-3 was associated with decrease in thyroid hormones 
in both background population and pregnant women (22, 
23) and when measured in urine of pregnant women, BP-3 
was associated with sex-dependent impact on birthweight 
(decreased in girls and increased in boys) (5) and decreased 
gestational length in boys (24). In the present study, we 
examined the associations of 2nd trimester maternal 
concentrations of three prevalently present UV filters 
(BP-1, BP-3 in maternal urine and 4-HBP in maternal 
serum) to maternal serum concentrations of thyroid 
hormones and growth factors and also to birth outcomes.
Materials and methods
Study population and materials
The study population consisted of participants in a study on 
the distribution of UV filters in urine, serum and amniotic 
fluid and consisted of 200 pregnant women undergoing 
amniocentesis at either Copenhagen University Hospital 
Hvidovre or Rigshospitalet. The study has previously been 
described in detail (3); in short, blood, urine and amniotic 
fluid samples were collected simultaneously from each 
woman during the second trimester of pregnancy when 
they arrived at the hospital for the amniocentesis procedure 
during the period September 2012 to August 2014. In 
the current study, only results measured from blood and 
urine are included. The indication for amniocentesis 
varied but largely the women could be divided into three 
groups according to the severity of the amniocentesis 
indication and outcome: group 1: women referred for 
amniocentesis solely because of maternal request and/or 
high maternal age and found to carry fetuses with normal 
karyotype and normal results of ultrasound scan; group 2 
women with increased risk for neural tube defects (NTDs), 
intestinal atresia, trisomy 18 or 21 or unspecific echogenic 
bowl on ultrasound scan, but who were found to carry 
a fetus without any malformations and with a normal 
karyotype and group 3: women carrying a fetus with 
either malformations found by ultrasound scan or with an 
abnormal karyotype, or both.
Information on maternal prepregnancy BMI, sex of 
the fetus, gestational age at sampling and at birth and 
birth outcome measured at delivery were all obtained 
from medical records.
Among the 200 pregnant women included in the 
study, 15 were excluded from analyses for the following 
reasons: medication for thyroid disease (n = 4), overtly 
pathological thyroid hormones at the time of sampling 
(n = 2), missing BMI information (n = 6) and missing infant 
sex information (n = 3) resulting in a total of 185 pregnant 
women. Due to missing serum samples from two of them, 
only 183 pregnant women were included in the analyses 
for thyroid hormones and growth factors collected at 
amniocentesis (study group 1, Fig.  1). Furthermore, 22 
of the women had an abortion after the samples were 
collected and in 6 additional cases all birth outcome data 
were missing, resulting in 157 mother–child pairs for the 
birth outcome analyses based on urine samples and 155 
mother–child pairs based on serum samples (study group 
2, Fig. 1). One hundred fifty-five of the mother–child pairs 
were included in both the analyses of maternal hormone 
concentrations and birth outcomes in relation to UV 
filter concentrations.
All participants signed a declaration of informed 
consent prior to sample collection. The study was 
approved by The Ethics Committee of the Capital Region 
of Denmark (H-2-2012-76) and by The Danish Data 
Protection Agency (2012-58-0004).
Hormone analyses
Maternal serum samples were stored at −20°C until 
analyzed in one batch in March 2016 for thyroid 
hormones and in March 2017 for growth factors, with 
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the exception of two samples, which were analyzed for 
thyroid hormones in March 2017.
The thyroid hormones triiodothyronine (T3), 
free triiodothyronine (fT3), thyroxine (T4) and 
free thyroxine (fT4) were measured by competitive 
electrochemiluminescence immunoassays (ECLIA) and 
thyroid-stimulating hormone (TSH) by a sandwich 
electrochemiluminescence immunoassay (ECLIA) on a 
Cobas 8000, Modular e602 (Roche) at the Department 
of Clinical Biochemistry, Rigshospitalet, University 
of Copenhagen, Denmark. Interassay coefficients of 
variation were <8% for all thyroid hormone assays. 
Limit of detection was 0.014 U/L, 0.3 nmol/L, 1.5 pmol/L, 
5.4 nmol/L, and 3 pmol/L for TSH, T3, fT3, T4 and fT4, 
respectively.
Analyzed growth factors included insulin-like growth 
factor I (IGF-I) and its major binding protein: insulin-
like growth factor-binding protein-3 (IGFBP3). IGF-I and 
IGFBP3 were both measured by a chemiluminescence 
immunoassay on the IDS-iSYS automated platform 
(Immuno Diagnostic Systems, IDS) at the Hormone 
Laboratory of the Department of Growth and 
Reproduction, Rigshospitalet, Copenhagen University, 
Denmark. Interassay coefficient of variation and limit of 
detection were respectively <13% and below 80 μg/L for 
IGFBP3 and <8% and 10 μg/L for IGF-I.
Chemical analysis of UV filters
Maternal urine and serum samples were analyzed for seven 
different UV filters by isotope dilution TurboFlow-liquid 
chromatography–tandem mass spectrometry (LC–MS/MS) 
(25), and the measured concentrations have previously 
been reported in detail (3). In the present study, only the 
three UV filters, which were present at concentrations 
above detection limits in more than 60% of samples are 
included: benzophenone-1 (BP-1) and benzophenone-3 
(BP-3) in maternal urine and 4-hydroxy-benzophenone 
(4-HBP) in maternal serum. The octanol/water partition 
coefficients (log Kow) of these three benzophenones 
indicate that they are sufficiently hydrophilic to not bio 
accumulate and urine is usually the preferred matrix for 
this kind of substances. However, we have previously 
shown that in paired urine and serum samples from this 
study population, 4-HBP was more frequently present in 
detectable concentrations in serum (88% of the samples) 
than in urine (21% of the samples) (3).
Adjustment for urinary dilution
In order to be able to adjust measured urinary 
concentrations of UV filters for the urinary dilution, 
the osmolality of the urine samples were measured by 
freezing point depression method with an automatic 
Figure 1
Study population and number of biological 
samples included in analyses on thyroid 
hormones and growth factors (study group 1) 
and in analyses on birth outcomes (study group 
2). 1Includes medication for thyroid disease (n = 4) 
and overtly pathological thyroid hormones at the 
time of sampling (n = 2).
Study population
Maternal blood (n=198)
Maternal urine (n=200)
Excluded due to
Thyroid disease1 (n=6)
Missing BMI (n=6)
Missing gender (n=3)
Study group 1:
Thyroid hormones and
growth factors analyses
Maternal serum (n=183)
Abortion (n=22)
Missing all birth outcome data (n=6)
Study group 2:
Birth outcome analyses
Maternal serum (n=155)
Maternal urine(n=157)
Excluded due to
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cryoscopic osmometer (Osmomat 030 from Gonotec, 
Berlin, Germany). Urinary osmolality was chosen as an 
adjustment method for urinary dilution as it was shown to 
be less affected by other exogenous factors in comparison 
to other known methods (26). Measured urinary UV filter 
concentrations were osmolality adjusted to account for 
urinary dilution using the following equation:
C Cicorr ref
meas
×Osm
Osm
=
where Ccorr is the corrected concentration, Ci is the measured 
biomarker concentration, Osmmeas is the measured 
osmolality in the sample and Osmref is the reference 
osmolality value corresponding to the median osmolality 
of all the included urine samples (= 0.376 osmol/kg).
Statistical analyses
Concentrations of UV filters below LOD were sat to 
the respective LOD divided by square root of two. The 
associations between measured concentrations of urinary 
BP-1, BP-3 and serum 4-HBP in pregnant women at 2nd 
trimester and their serum concentrations of thyroid 
hormones, the growth factors IGF-I and IGFBP3 as well 
as the birth outcomes of their infants were examined by 
General Linear Models (GLM). The exposure biomarkers 
were entered individually in the models as either a 
continuous or a categorical independent variable: 
concentrations of BP-3 and 4-HBP were grouped into 
the low, medium and high exposure categories based 
on the tertiles. For BP-1, the fraction of samples with 
undetectable concentrations exceeded 33%, and for this 
compound, all undetectable samples were categorized to 
the low exposure group, while the rest of the samples were 
distributed equally into the medium and high exposure 
groups (for boundaries of the categories, Table  2). The 
distribution into low, medium and high exposure 
categories were made separately for models of associations 
with maternal thyroid hormones and growth factors and 
for models of association with birth outcomes because of 
a different number of samples included in the models of 
the different outcomes (Fig. 1).
Potential covariates in the study were maternal 
prepregnancy BMI (both as a continuous and a categorical 
(<20, 20–25, >25) variable), maternal smoking, parity, 
maternal age, maternal educational status, sex of the fetus 
and gestational age (either at time of sampling for models 
of associations with maternal hormones, or at birth for 
models of associations with birth outcomes) and season 
(Summer = May–August, Winter = September–April) of 
sampling. The influence of the potential covariates was 
checked by including them in the GLM one by one. Sex 
and gestational age of the infant and maternal BMI had 
all influence on statistical significance, defined as P value 
below or above 0.05 of the final result of examined GLM. 
Gestational age at sampling and maternal prepregnancy 
BMI were entered as covariates in all analyses of the 
association with maternal hormones, while gestational 
age at birth and prepregnancy BMI were used as covariates 
in all analyses of the associations with birth outcomes. 
The impact of maternal prepregnancy BMI in the model 
was not linear and BMI was therefore included as a 
categorical variable (<20, 20–25 and >25). Furthermore, 
all analyses were stratified on the sex of the fetus because 
the concentrations of placental growth hormone (a major 
regulator of maternal IGF-I production during pregnancy) 
(27, 28) are known to be affected by fetal sex (29, 30), and 
birth outcomes in general are sex dimorphic (31).
In subsequent sensitivity analyses, we also included 
maternal smoking as a confounder in the full model of 
associations of the exposure biomarkers to birth outcomes 
because maternal smoking is well known to be associated 
with decreased birth weight (32). Likewise, in additional 
sensitivity analyses, we included season of sampling 
and season at birth as a confounder in the full model of 
associations of the exposure biomarkers to respectively 
maternal hormone concentrations and birth outcomes, 
showing that season did not have any significant impact 
on the results (data not shown).
Furthermore, as intrauterine growth retardation 
(IUGR) can be caused by several factors not related to 
endocrine factors, we repeated all analyses on birth 
outcome with exclusion of all IUGR pregnancies (n = 20, 
IUGR defined according to the Danish national guideline 
as fetal weight below the 10th percentile for gestational 
age as determined through ultrasound) to see whether it 
changed the results of the final model.
Although UV filters concentrations were not 
normally distributed, transformation of the data was not 
necessary to achieve normal distribution and constant 
variance of the standardized residuals of GLM examined 
by visual inspection of the plots. All the statistical 
analyses described earlier were performed in IBM 
SPSS 22.
Due to the biological association between IGF-I and 
its binding protein IGFBP3, we calculated mediation 
proportion in order to examine whether observed 
associations of the exposure biomarkers to IGF-I were 
directly associated or possibly mediated through IGFBP3. 
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Calculations of mediation proportions were performed 
in the lava-package (version 1.5.1 (33)) in the statistical 
software ‘R’ (version 3.3.2 (34)).
Results
Basic characteristics of the women included in the 
study are presented in Table  1 for the full study group 
and stratified by three amniocentesis (AC) subgroups 
based on the severity of the indication and outcome 
of the amniocentesis as indicated in the ‘Materials 
and methods’ section. Women in AC subgroup 1 were 
older and had statistically significantly lower 4-HBP 
serum concentrations than the two other subgroups. 
Supplementary statistical analyses showed that maternal 
4-HBP levels were associated with age (data not shown) 
and the difference in 4-HBP concentrations between the 
AC group 1 and the two other groups could be explained 
Table 1 Characteristics of the included pregnant women.
All (n = 183) (100%) AC group 1 (n = 41) (22%) AC group 2 (n = 75) (41%) AC group 3 (n = 67) (37%) P valuea
Age (median (range)) 34 (21–44) 37 (27–42) 34 (21–42) 33 (21–44) 0.003a,c
Education (n (%))
High 123 (67.2) 30 (73.2) 48 (64.0) 45 (67.2) 0.364e 
Middel 31 (16.9) 8 (19.5) 15 (20.0) 8 (11.9)
Low 27 (14.8) 3 (7.3) 12 (16.0) 12 (17.9)
Prepregnancy body mass index (BMI) (n (%))
BMI: ≤20 39 (21.3) 7 (17.1) 22 (29.3) 10 (14.9) 0.005e 
BMI: >20–25 95 (51.9) 28 (68.3) 27 (36.0) 40 (59.7)
BMI: >25 49 (26.8) 6 (14.6) 26 (34.7) 17 (25.4)
Smoking (n (%))
No smoking 138 (75.4) 32 (78.1) 57 (76.0) 49 (73.1) 0.633e 
Passive smoking 32 (17.5) 6 (14.6) 13 (17.3) 13 (19.4)
Nicotine 5 (2.7) 0 2 (2.7) 3 (4.5)
Smoking 8 (4.4) 3 (7.3) 3 (4.0) 2 (3.0)
Parity (n (%))
Nuliparous 69 (37.7) 13 (31.7) 28 (37.3) 28 (41.8) 0.574e 
Multiparous 113 (61.7) 28 (68.3) 46 (61.3) 39 (58.2)
Comorbidity (n (%))
No comorbidity 76 (41.5) 16 (39.0) 32 (42.7) 28 (41.8) 0.568e 
1 comorbidity 54 (29.5) 9 (22.0) 24 (32.0) 21 (31.3)
≥2 comorbidities 53 (29.0) 16 (39.0) 19 (25.3) 18 (26.9)
Pregnancy resulting in a 
liveborn child (n (%))
161 (88.0) 40 (97.6) 75 (100) 46 (68.7) <0.005a,f
Gestational week at AC 
(median (range))
18 (12–36) 16 (15–36) 16 (12–25) 20 (15–34) <0.005a,d
Maternal serum hormone concentrations at AC (median (range))
TSH (IU/L) 1.8 (0.1–6.5) 1.8 (0.7–6.5) 1.7 (0.2–4.0) 2.0 (0.1–4.1) 0.077g
T3 (nmol/L) 2.4 (1.5–3.9) 2.3 (1.5–3.5) 2.4 (1.7–3.9) 2.4 (1.7–3.6) 0.131
g
fT3 (pmol/L 4.6 (3.5–6.1) 4.6 (3.5–5.6) 4.7 (3.8–5.8) 4.7 (3.8–6.1) 0.703
g
T4 (nmol/L) 143 (96.7–214) 139 (97.3–175) 146 (96.7–212) 141 (101–214) 0.103
g
fT4 (pmol/L) 14.2 (10.1–20.0) 14.2 (10.9–17.3) 14.4 (11.2–18.0) 13.8 (10.1–20.0) 0.060
g
IGF-I (µg/L) 126 (11.4–282) 121 (57.5–195) 123 (11.4–220) 127 (67.9–282) 0.545g
IGFBP3 (µg/L) 4846 (3013–7961) 4858 (3013–7401) 4794 (3337–7961) 4850 (3369–7566) 0.901g
Maternal UV filter concentrations at AC (median (range))
uBP-1 (ng/mL)b 0.47 (LOD-665) 0.60 (LOD-337) 0.27 (LOD-665) 0.57 (LOD-610) 0.368g
uBP-3 (ng/mL)b 2.57 (LOD-10,034) 3.83 (LOD-1613) 2.12 (LOD-10,034) 2.60 (LOD-2986) 0.539g
s4-HBP (ng/mL) 0.65 (LOD-1.96) 0.54 (LOD-1.85) 0.68 (LOD-1.87) 0.70 (LOD-1.96) 0.046a,h
AC groups: Pregnancies stratified into three groups according to the severity of the indication for and outcome of the amniocentesis as described 
in the ‘Materials and methods’ section.
aStatistical significant differences between the AC groups, P-value <0.05; bosmolality adjusted concentrations; cKruskal–Wallis test: Group 1 was 
significantly older than the other two groups; dKruskal–Wallis test: Gestational age at amniocentesis was significantly higher in group 3; 
eChi-square test; fChi-square test: Number of life born children was significantly lower in group 3; gKruskal–Wallis test; hKruskal–Wallis test: Serum 
concentrations of 4-HBP were significantly lower in group 1.
AC, amniocentesis; fT3, free triiodidothyronine; fT4, free thyroxine; IGF-I, insulin-like growth factor I; IGFBP3, insulin-like growth factor binding 
protein 3; s4-HBP, serum 4-hydroxy benzophenone; T3, triiodothyronine; T4, thyroxine; TSH, thyroid stimulating hormone; uBP-1, urinary 
benzophenone 1; uBP-3, urinary benzophenone 3.
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by the difference in age. As the three subgroups did not 
differ significantly from each other on any of the other 
parameters studied, all subsequent analyses were done on 
the full study group.
The distribution of maternal urinary BP-1 and BP-3 
concentrations and maternal serum 4-HBP concentrations 
in the three exposure groups used when modeling 
exposure as a categorical variable are shown in Table 2. 
Median and range of the birth outcomes of the infants, 
obtained from medical records, are shown in Table  3 
stratified by sex of the child.
Associations between maternal UV filter 
concentrations and maternal thyroid hormones and 
growth factors
For maternal urinary BP-1 and BP-3 concentrations, no 
statistically significant associations (P values: >0.05) 
to maternal thyroid hormones, IGF-I or IGFBP3 were 
observed (data not shown).
For women carrying a male fetus, we observed 
significant positive associations between maternal serum 
4-HBP concentrations and maternal T3, T4, IGF-I and 
IGFBP3 concentrations when adjusted for gestational 
age at sampling. These associations remained significant 
for IGF-I and IGFBP3 when additionally adjusted 
for prepregnancy BMI (Supplementary Table  1.1, see 
section on supplementary data given at the end of this 
article). The effect estimates indicated that an increase 
of 1 ng/mL in maternal 4-HBP serum concentrations was 
associated with an average increase in maternal serum 
concentrations of T3 of 0.27 nmol/L (95% CI: 0.05–0.49, 
P = 0.02) and T4 of 11.9 nmol/L (95% CI: 0.66–23.0, 
P = 0.04) when adjusted for gestational age at sampling, 
and an increase in IGF-I of 19 μg/L (95% CI: 1.4–37, 
P = 0.04) and IGFBP3 of 516 μg/L (95% CI: 72.8–959, 
P = 0.02) when adjusted for both gestational age and 
maternal prepregnancy BMI.
For women carrying a female fetus, no associations 
between maternal serum 4-HBP and maternal T3 or T4 
were observed (Supplementary Table  1.2) but instead 
a significant negative association with maternal fT4 
concentrations was observed. The effect estimates indicate 
that an increase of 1 ng/mL in 4-HBP serum concentrations 
was associated with an average decrease of maternal fT4 
serum concentrations of 1 pmol/L (95% CI: −0.14 to 
(−1.88), P = 0.02). The associations between maternal 
serum 4-HBP and maternal growth factors were less 
pronounced for women carrying a female fetus, although 
a positive trend with serum IGFBP3 concentrations was 
still evident, with women in the highest exposure group 
having significantly higher IGFBP3 serum concentrations 
than women in the lowest exposure group (P = 0.04). Effect 
estimates for the association between maternal serum 
4-HBP and maternal serum IGFBP3 were of the same order 
as observed for women carrying a male fetus.
Serum IGF-I and IGFBP3 concentrations are known to 
be highly correlated (27) and in order to test whether the 
association between maternal serum 4-HBP and maternal 
Table 3 Median and range for birth outcome variables in 
the newborn girls and boys.
Median Min Max
Female infants (n = 72)
 Gestational age (weeks) 39 33 42
 Weight (g) 3246 1351 4385
 Length (cm)a 50 42 57
 Head cir. (cm)a 34 29 38
 Abdominal cir. (cm)b 32 22 38
Male infants (n = 85)
 Gestational age (weeks) 40 32 42
 Weight (g)c 3494 1560 4916
 Length (cm) 51 39 56
 Head cir. (cm) 35 28 38
 Abdominal cir. (cm)b 33 26 38
aBirth length and birth head circumference in female infants were 
available only in 71 cases; bbirth abdominal circumferences were available 
only in 83 cases for male infants and in 68 cases for female infants; cbirth 
weight for male infants was available only in 84 cases.
Table 2 Distribution of second trimester maternal urinary (u) benzophenone-1 (BP-1) and benzophenone-3 (BP-3) 
concentrationsa (ng/mL) and serum (s) 4-hydroxy-benzophenone (4-HBP) concentrations (ng/mL).
 
UV filter
 
n > LOD (%)
 
LODb
 
Min
 
Median
Exposure groups  
MaxLow (n) Middle (n) High
uBP-1 119 (65) 0.25 <LOD 0.47 <LOD (68)c 0.25–1.61 (58) >1.61 (57) 665
uBP-3 168 (92) 0.28 <LOD 2.57 <1.23 (61) 1.23–6.66 (61) >6.66 (61) 10,034
s4-HBP 161 (88) 0.18 <LOD 0.65 <0.48 (61) 0.48–0.83 (61) >0.83 (61) 1.96
Stratification into exposure tertiles is based on study population 1 (n = 183).
aOsmolality adjusted concentrations; blimit of detection (ng/mL) for raw measurements before osmolality adjustment; cthe number of samples in the low 
exposure group to BP-1 exceeds the number of samples below LOD because four samples in the low exposure group to BP-1 were >LOD before 
osmolality adjustment but gave a value <0.25 (ng/mL) after osmolality adjustment.
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IGF-I was modified by IGFBP3 concentrations, we 
calculated the mediation coefficients for the association of 
4-HBP concentrations in maternal serum on IGFBP3 and 
IGF-I split by sex of the fetus (Table 4). It was estimated 
that in the boys, 35% of the association of serum 4-HBP to 
maternal IGF-I could be mediated via an association with 
IGFBP3 serum concentrations (P = 0.05).
Associations between maternal UV filter 
concentrations in the second trimester and 
birth outcomes
For male infants of the mothers in the medium 4-HBP 
exposure group, we observed significantly lower birth 
weight and smaller head and abdominal circumferences 
(P = 0.04; P = 0.04; P = 0.008 respectively). These associations 
remained significant when adjusted for gestational age at 
birth and prepregnancy BMI (Fig.  2 and Supplementary 
Table  2). Adjustment for smoking did not change the 
results (data not shown). The effect estimates indicate 
that boys of mothers from the medium 4-HBP exposure 
group at birth were on average 240 g lighter, 8 mm smaller 
in head circumference, and 1.6 cm smaller in abdominal 
circumference compared to boys of mothers in the low 
exposure group when adjusted for prepregnancy BMI 
and gestational age at birth. When IUGR pregnancies 
were excluded from the models, negative associations 
with head and abdominal circumferences in male infants 
of mothers in the medium exposure group were still 
significant (P = 0.05 and P = 0.01, respectively (data not 
shown)). When 4-HBP concentrations were included in 
the model as continuous variable, we did not observe any 
significant association between maternal serum 4-HBP 
concentrations in the second trimester and any of the 
recorded birth outcomes in male infants (Supplementary 
Table 2).
For female infants, there was no significant association 
between maternal serum 4-HBP concentrations in 
the second trimester and any of the recorded birth 
outcomes (Supplementary Table  2), when adjusting for 
gestational age at birth. However, in the model where 
IUGR pregnancies (n = 20) were excluded, we observed 
a significantly positive association between maternal 
serum concentrations of 4-HBP and birth length and head 
circumference in female infants both when the 4-HBP 
serum concentration were used as a continuous (P = 0.03 
and P = 0.02 respectively) and a categorical (trend P = 0.05 
and trend P = 0.04 respectively) exposure marker (data not 
shown).
For mothers carrying a male fetus, we observed 
significantly negative associations of abdominal 
circumference at birth with maternal urinary 
concentrations of BP-1 (P value = 0.01) and BP-3 (P value 
<0.007) (data not shown). However, this association 
was driven by a single mother, who had very high 
BP-1 (665 ng/mL) and BP-3 (5893 ng/mL) urinary 
concentrations compared to the other women and whose 
son was one of the smallest in the study in spite of being 
born at term. When this mother–child pair was excluded 
from the models, the associations between BP-1 and BP-3 
and abdominal circumference were no longer statistically 
significant. Also one of the mothers carrying a female 
fetus had high urinary concentrations of BP-1 and BP-3 
(612 ng/mL and 10,034 ng/mL, respectively). No significant 
associations between maternal urinary concentrations of 
BP-1 and BP-3 and birth outcomes in female fetuses were 
observed, regardless if this high exposed mother–female 
infant pair was included in the model or not.
Discussion
In our prospective study of 183 pregnant women, 
we examined the relationship between 2nd trimester 
exposure to UV filters of the benzophenone type and 
maternal thyroid hormones, growth factors and birth 
variable outcomes. We found statistically significant 
positive association between 4-HBP concentrations in 
maternal serum and T4, IGF-I and IGFBP3 in mothers 
carrying male fetuses. Furthermore, we observed 
consistent negative associations in male offspring between 
maternal serum concentrations of 4-HBP and all birth 
endpoints, although only statistically significant for 
Table 4 Mediation coefficient for the estimated effect of 
1 ng/mL increase in 4-hydroxybenzophenone (4-HBP) 
concentrations in maternal serum on insulin-like growth 
factor I (IGF-I) (μg/L) directly or indirectly mediated by 
insulin-like growth factor binding protein 3 (IGFBP3).
 
 
Effect
 
Mediation 
coefficient
 
 
95% CI
% of 
the 
effect
 
 
P-Value
Male
 Total 19.3 2.65 36.0 100 0.02
 Direct 12.5 −3.65 28.6 65 0.13
 Indirect 6.84 0.04 13.64 35 0.05
Female
 Total 10.8 −10.5 32.1 100 0.32
 Direct 4.27 −16.5 25.0 40 0.69
 Indirect 6.52 −1.31 14.4 60 0.10
CI, confidence interval.
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birth weight, head and abdominal circumferences, and 
only for sons of mothers in the middle exposure range. 
Thus, the associations between 4-HBP and birth outcomes 
appeared to be U-shaped rather than linear. A non-
monotonic dose–response relationship is a phenomenon 
that has been demonstrated in experimental studies for 
endocrine-disrupting effects of several chemicals (35, 36), 
and we speculate that 4-HBP might act in the same way 
in humans.
With regard to the UV filters BP-1 and BP-3, we did 
not observe any associations between maternal urinary 
concentrations and either maternal thyroid hormones, 
growth factors or birth outcomes. To our knowledge, BP-3 
is the only chemical UV filter for which maternal exposure 
has previously been examined in humans in relation to 
maternal thyroid hormones and birth outcomes. A recent 
study reported negative association between maternal 
urinary BP-3 and serum fT3 concentrations (22). In that 
study, the concentrations of BP-3 found in maternal 
urine were about 3- 4-fold higher than those in our study 
population. Furthermore, they did not analyze their data 
stratified by sex of the infant. These differences could 
possibly explain the difference in findings between the 
two studies.
Results of previous studies regarding associations 
between maternal urinary BP-3 concentrations and birth 
outcome are equivocal as associations between maternal 
urinary BP-3 concentrations were observed to be either 
positively associated with birth weight in boys and 
negatively associated with birth weight in girls (5) or not 
Figure 2
Associations between maternal exposure to 
4-HBP (low: <0.48 (ng/mL) (n = 51) middle: 
0.48–0.788 (ng/mL) (n = 52) and high: >0.788 (ng/
mL) (n = 52)) and birth outcomes in male (n = 85) 
and female infants (n = 72). Stratification into 
exposure tertiles is based on study group 2 
(n = 155). *P < 0.05.
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associated to birth weight at all (4, 24). Maternal urinary 
BP-3 concentrations in the American study (5), which 
observed associations with birth weight, were on average 
3-fold higher than those observed in our Danish study 
population and in a French study population (4) and 
100-fold higher than those observed in a Chinese study 
population (24); all of which did not observe a significant 
associations for BP-3 to birth weight. It is possible that 
associations between maternal BP-3 concentrations and 
birth weight are only observed at BP-3 exposure level 
higher than those measured in our study; a study with 
a larger range of exposure levels would be required to 
demonstrate whether this is the case.
Maternal exposure to endocrine-disrupting chemicals 
can affect the fetus by acting directly on the fetus if the 
fetus is co-exposed through placental transfer of the 
chemical. However, endocrine-disrupting effects can also 
affect the fetus indirectly via changes in maternal hormone 
concentrations, including thyroid hormones (37) and 
growth factors (38, 39, 40, 41). We observed associations 
between maternal serum concentrations of 4-HBP and 
maternal thyroid status, and interestingly, the observed 
associations differed depending on the sex of the fetus. 
For mothers carrying a female fetus, the effect estimates 
indicate that, in relation to median fT4 concentrations, 
the highest exposed mothers might have on average 12% 
lower fT4 concentrations compared to the lowest exposed 
mothers. For mothers carrying a male fetus, the highest 
exposed mothers might have on average 20% and ~22% 
higher serum T3 and T4 concentrations, respectively, 
than the lowest exposed mothers. During pregnancy, the 
fetus is highly dependent on maternal thyroid hormone 
function, especially during the first 20 weeks of gestation. 
Thyroid receptors, thyroid receptor gene expression 
and prereceptor control mechanisms are detected in 
fetal tissues as early as at gestational week 7 (42, 43), 
demonstrating the importance of thyroid hormones for 
fetal development already in early pregnancy, long before 
the fetus’s own thyroid hormone production initiates 
around gestational week 11 and is fully established around 
mid-gestation (44). Experimental studies indicate that the 
active hormone T3 is not transferred from the mother 
to the fetus; the fetal source comes from metabolism of 
maternal T4 reaching fetal tissue; thus, only fT4 passes 
the placental barrier from maternal circulation to meet 
the fetal requirements (45). Even at term, 30% of the 
fetal thyroid hormones are of maternal origin (44). Low 
maternal concentrations of fT4 during early pregnancy, as 
we observed in the high 4-HBP exposed women carrying 
a female fetus, have been shown to affect both verbal and 
nonverbal cognitive function of infants later in life (46). 
Hyperthyroidism during pregnancy has, on the other 
hand, been shown to be associated with increased risk 
of low birth weight and being small for gestational age 
(47, 48), which is in agreement with our observation of 
4-HBP exposure in women carrying a male fetus being 
associated with both increased maternal thyroid hormone 
concentrations and decreased fetal growth. Thus, it is 
possible that the association with birth size of male 
offspring in mothers of the middle exposure group to 
4-HBP could be mediated by an increase in their thyroid 
hormones. However, we have previously shown that 
4-HBP also might enter the fetal circulation and hence 
might also act directly on the fetus (3).
We also observed positive associations between 
maternal serum concentrations of 4-HBP and of the 
growth factor IGF-I and its major binding protein IGFBP3. 
During pregnancy, maternal serum concentrations 
of IGF-I and IGFBP3 increase to reach a maximum at 
approximately 37  weeks of gestation (27). This increase 
is positively associated with an increase in placental-
derived growth hormone (pGH), which is detectable in 
maternal serum from week 8 (49) and gradually takes 
over the function of maternal pituitary growth hormone, 
which concurrently decrease during pregnancy (38). In 
the second trimester, pGH therefore plays an important 
role in stimulating maternal IGF-I production (38, 50) 
(and indirectly also IGFBP3 production (27)). Maternal 
IGF-I on the other hand stimulates placental nutrition 
transport to the fetus (51, 52, 53, 54). Maternal IGF-I has 
been shown to be associated with placental weight and is 
believed to be indirectly responsible for fetal growth (27). 
It therefore seems contradictive that maternal exposure to 
4-HBP is associated with both increased maternal IGF-1 
concentrations and decreased fetal growth as we observed 
for the boys.
4-HBP is known to be one of the metabolites of 
benzophenone (BP), and the measured maternal serum 
concentrations of 4-HBP may therefore, at least partly, 
originate from exposure to BP and maternal metabolism of 
BP into 4-HBP (55). However, 4-HBP is also in itself used in 
industry as a UV absorber and in the manufacture of other 
substances (6) but not in sunscreens or other personal care 
products (9). BP is also not allowed to be used in sunscreens 
as a UV filter, but is still allowed for use in personal care 
products as flavoring and perfume fixation. In addition, BP 
is used in washing agents, painting, fillers, pharmaceuticals, 
lacquers, furniture, electrical equipment and flavoring 
in candies, and also as a photo-initiator, surfacing and a 
wetting agent in inks, which often lead to its presence in 
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recycled paper (10). Experimental studies elucidating effects 
of 4-HBP exposure are limited but 4-HBP exposure has been 
reported to exhibit an estrogenic activity both in vitro and 
in vivo, while the parent compound BP only shows a weak 
or no estrogenic activity (16, 21, 56). In humans, maternal 
urinary 4-HBP concentrations have been associated with a 
skewed sex ratio with an excess of male birth (13). BP has 
been shown in vitro to decrease thyroid peroxidase (TPO) 
activity that plays an important role in thyroid hormone 
synthesis (20). We do not know if BP is metabolized to 
4-HBP in the used in vitro model (a follicular thyroid 
carcinama cell line) and the observed effect therefore 
potentially could be mediated (partly) by 4-HBP. With a 
decrease in TPO activity reduced T3 and T4 synthesis would 
be expected, which is the opposit of our findings where we 
observe higher T3 and T4 concentrations with higher 4-HBP 
concentrations in mothers carrying male infants. However, 
in contrast to an in vitro model, all the compensatory feed 
back mechanisms are active in our pregnant women and 
an effect observed in an in vitro system is therefore difficult 
to translate into potential effects in vivo.
Limitations and strengths of the study
A limitation of our study is that maternal exposure was 
estimated based on single spot urine and serum samples. 
The benzophenone type UV filters are non-persistent 
chemicals that are expected to be excreted within a few 
days (depending on the chemical) and thus a concentration 
measured at a given time reflects only recent exposure. 
However, intra-individual urinary concentrations of BP-3 
have previously been shown to have a relatively high 
interclass correlation coefficient (ICC) ranging from 0.46 
to 0.81 (57, 58, 59) and was demonstrated to be well 
correlated with other spot samples taken during a longer 
period within the same individual (59, 60, 61). Therefore, 
at least for BP-3 but most likely also for BP-1 and 4-HBP, 
the concentrations measured in a single spot sample 
is assumed to represent quite well a person’s general 
exposure level. Furthermore, based on our previous study 
examining several UV filters in different matrices (3), we 
were able to focus on the most appropriate matrices for 
BP-1, BP-3 and 4-HBP exposure in this study.
The gold standard for measurement of free thyroid 
hormones (fT3 and fT4) is a method involving a separation 
step of bound from free thyroid hormone, classically a 
dialysis method (62) or recently the LC/MS method; but 
none of these methods are widely available. In our study, 
free thyroid hormones were measured by an immunoassay. 
Immunoassays can both overestimate and underestimate 
free thyroid hormone concentrations depending on the 
platform used for the assay (62). However, there is no 
reason to suspect that a potential overestimation of free 
T3 and free T4 serum concentrations should be biased in 
relation to the exposure to UV filters and thereby might 
not have affected the results.
Sample size is always a challenge in studies like this 
and is limited both by recruitment and cost of analyses. 
Our study population was a selected group of women 
undergoing amniocentesis. However, with regard to their 
exposure to UV filters, we do not think that they are biased 
compared to the general population for the following 
reasons: (1) when adjusting for the age of the mother, no 
significant difference in exposure levels were observed 
between the women carrying a fetus with malformations 
or abnormal karyotype and the women carrying a healthy 
fetus with maternal age or wish as only indication for 
the amniocentesis procedure and (2) the concentrations 
of maternal urinary BP-1 and BP-3 measured in our 
study population was comparable to the concentrations 
recently measured in pregnant women from the general 
population (1).
We analyzed the associations of exposure to three 
different UV filters against seven different hormones and 
four different birth outcomes, resulting in a large number 
of tests which increased the risk of a significant result being 
a chance finding. We thus cannot exclude that some of our 
significant associations were chance findings. However, 
the reported findings, especially those observed in male 
infants, all point in the same direction and are in mutual 
biological agreement, making them plausible true findings.
Conclusion
In conclusion, in this prospective study of 183 mother–
child pairs, we found associations between maternal 
serum concentrations of the UV filter 4-HBP (used a UV 
absorber in industrial products) and decrease in birth 
weight, birth abdominal- and head circumference in 
male infants. In addition, we found an association with 
changes in thyroid hormone concentrations and growth 
factors, predominantly in mothers carrying male fetuses. 
Those findings are of concern and call for further studies 
on possible long-term consequences of exposure to UV 
filters for fetal development and children’s health.
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